Saturday January 18, 2020 03:28

Heathcare Press Release : 11 Sep 2019

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Heathcare—11 Sep 19

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with